NCT05564780

Study of Early Pharmaceutical Intervention for Cardiovascular Disease Prevention in Stage 1 Hypertension

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 20,000 (estimated)
• Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital · Academic / Other
• Sex: All
• Age: 35 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

STEP-Pre is to investigate the benefits of using anti-hypertensive drugs in the population with a blood pressure of 130-139/80-89 mmHg and evaluate the health economics. STEP-Pre is a multi-center randomized clinical trial. The cohort will be randomized into the treatment group or control group with a 1:1 ratio. The treatment group will take anti-hypertensive medicine to control blood pressure under 130/80 mmHg. Both groups will take health care education. STEP-Pre will last 4 years.

Conditions

• Cardiovascular Diseases

Interventions

Type	Name	Description
DRUG	RASI and/or a single pill combination based RASI	The participants in the Treatment group will begin with a single category antihypertensive drug to control their blood pressure, for example, perindopril. If the blood pressure cannot be controlled under 130/80 mmHg, another type of antihypertensive drug will be added.

Timeline

• Start date: 2023-01-01
• Primary completion: 2026-12-31
• Completion: 2026-12-31
• First posted: 2022-10-04
• Last updated: 2022-10-04